TY - JOUR AU - Collins, Matthew AU - McGowan, Eileen AU - Jadi, Ramesh AU - Young, Ellen AU - Lopez, Cesar AU - Baric, Ralph AU - Lazear, Helen AU - de Silva, Aravinda T1 - Lack of Durable Cross-Neutralizing Antibodies Against Zika Virus from Dengue Virus Infection T2 - Emerging Infectious Disease journal PY - 2017 VL - 23 IS - 5 SP - 773 SN - 1080-6059 AB - Cross-reactive antibodies elicited by dengue virus (DENV) infection might affect Zika virus infection and confound serologic tests. Recent data demonstrate neutralization of Zika virus by monoclonal antibodies or human serum collected early after DENV infection. Whether this finding is true in late DENV convalescence (>6 months after infection) is unknown. We studied late convalescent serum samples from persons with prior DENV or Zika virus exposure. Despite extensive cross-reactivity in IgG binding, Zika virus neutralization was not observed among primary DENV infections. We observed low-frequency (23%) Zika virus cross-neutralization in repeat DENV infections. DENV-immune persons who had Zika virus as a secondary infection had distinct populations of antibodies that neutralized DENVs and Zika virus, as shown by DENV-reactive antibody depletion experiments. These data suggest that most DENV infections do not induce durable, high-level Zika virus cross-neutralizing antibodies. Zika virus–specific antibody populations develop after Zika virus infection irrespective of prior DENV immunity. KW - viruses KW - Zika virus KW - dengue virus KW - cross-neutralizing antibodies KW - vector-borne infections KW - flaviviruses KW - DENV KW - United States KW - Vaccine DO - 10.3201/eid2305.161630 UR - https://wwwnc.cdc.gov/eid/article/23/5/16-1630_article ER - End of Reference